A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Completed · Phase 3 · NCT04436640
Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
At a glance
- Research payments reported, 2025
- $118,767
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 508
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Bimekizumab (drug)
- Dates
- Started 2020-06-16; completion 2026-08-09
- Results posted
- Not yet
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $118,767 in research payments for this study in 2025 (86 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Areena Swarup, MD Rheumatology · Mesa, AZ
- Eric C. Lee, M.D. Specialist · Upland, CA
- Mary P. Howell, MD Internal Medicine · Hagerstown, MD
- Atulya A. Deodhar, MD Rheumatology · Portland, OR
- Alan Kivitz, MD Rheumatology · Duncansville, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ohsu Hospital and Clinics, OR $41,013
- Arizona Arthritis and Rheumatology Research $40,784
- Mayo Clinic Rochester $18,691
- Klein & Associates MD PA $17,380
- Weitzner, Yonker, Kaine MD. $900
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.